OptimizeRx Corporation Common Stock (OPRX) Stock
Key stats
- Market cap
- $168.58M
- Price / Earnings ratio
- 38.3x
- EPS (TTM)
- $0.24
- Volume
- Loading
- 52-week high
- $16.84
- 52-week low
- $4.54
Source: third-party data provider, as of November 13, 2026
Compare with OPRX
Recent news

OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network
OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network
OPRX

OptimizeRx Q2 Earnings Call Highlights
OptimizeRx Q2 Earnings Call Highlights
OPRX

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OPRX

OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OPRX
Technical indicators
- RSI 14
- 50.42
- MACD 12/26/9
- 0.21
- EMA 9 of MACD
- 0.27
- MACD histogram
- -0.06
- SMA 50
- $8.42
- Price above SMA 50
- EMA 50
- $8.53
- Price above EMA 50
- SMA 200
- $7.19
- Price above SMA 200
- EMA 200
- $8.50
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network
OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network
OPRX

OptimizeRx Q2 Earnings Call Highlights
OptimizeRx Q2 Earnings Call Highlights
OPRX

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OPRX

OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OPRX

OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX

OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OPRX

OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OPRX

OptimizeRx Q1 Earnings Call Highlights
OptimizeRx Q1 Earnings Call Highlights
OPRX

OptimizeRx Corp. (OPRX) Surpasses Q1 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) Surpasses Q1 Earnings and Revenue Estimates
OPRX

OptimizeRx Expands EHR Advertising Reach With New DSP Integration
OptimizeRx Expands EHR Advertising Reach With New DSP Integration
OPRX
About OptimizeRx Corporation Common Stock
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen L. Silvestro | CEO & Director | 1978 |
| Mr. Brendan Merrell | Chief Operating Officer | 1985 |
| Mr. Edward Stelmakh C.M.A., M.B.A. | Chief Financial & Strategic Officer | 1966 |
| Ms. Theresa Greco | Advisor | 1973 |
| Ms. Marion K Odence-Ford | Chief Legal & Administrative Officer | 1965 |
| Ms. Maira Alejandra | Media Relations Manager | — |
| Ms. Sarah Bast | Chief Marketing Officer | — |
| Mr. Andrew Jacob D'Silva | Chief Business Officer | 1986 |
| Jennifer Dinkel | SVP of Marketing | — |
| Mr. Mike Rouselle | Chief AI Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.42
- MACD 12/26/9
- 0.21
- EMA 9 of MACD
- 0.27
- MACD histogram
- -0.06
- SMA 50
- $8.42
- Price above SMA 50
- EMA 50
- $8.53
- Price above EMA 50
- SMA 200
- $7.19
- Price above SMA 200
- EMA 200
- $8.50
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $11.00
- Average
- $11.00
- High
- $11.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.2 | -5.0 | -22.5 | +6.3 | -0.5 | +21.8 | +6.2 | +11.1 | -0.6 |



